Navigation Links
SteriFx Inc. Provides 'Solutions' to Combat Campylobacter
Date:3/25/2009

Antimicrobial Developer Adds New Measurement Tool to Assist Processing Plants.

SHREVEPORT, La., March 25 /PRNewswire/ -- Since 2003, SteriFx Inc. and its FreshFx antimicrobial solutions have proven to be effective on the poultry processing line against Campylobacter jejuni (Campy), as well as Salmonella, E. coli, and Listeria. Now SteriFx can provide plant management another tool to help control Campylobacter by pre-screening birds for their current load of Campy at various points throughout processing.

"SteriFx now has the ability to measure levels of Campylobacter, and we can help processors get current levels in order to be better prepared for any new testing requirements," said John R. Dankert, Ph.D., CEO of SteriFx. "We have been successful in this regard for Salmonella, E. coli, and aerobic counts, and now can offer Campylobacter analysis."

Campylobacter species have been recognized as one of the leading causes of food illness in the United States. According to the Centers for Disease Control and Prevention (CDC), Campy is diagnosed in 13 cases each year for every 100,000 persons - although many more cases go undetected. It is estimated to impact over 2.5 million people annually, with 100 to 200 deaths per year. A substantial portion of the illnesses and deaths are associated with meat and poultry.

To combat Campy in poultry processing plants, SteriFx personnel can provide Microbiological Testing Services, from collection of samples to data analysis. By using FreshFx antimicrobial solutions as part of a company's Hazard Analysis and Critical Control Points (HACCP) efforts, it can control Campy and other pathogens - greatly reducing the risk of product recalls and helping to maintain consumer health.

FreshFx antimicrobial solutions are clear, odorless, digestible aqueous liquids that are non-toxic despite the low pH. They are easy-to-use
'/>"/>

SOURCE SteriFx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Dr. Kenneth L. Byrd Joins SteriFx Inc.
2. Study provides hope that some transplant patients could live free of antirejection drugs
3. Study provides hope that some transplant patients could live free of anti-rejection drugs
4. USAID Provides Additional Wildfire Assistance to Greece
5. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
6. New knock-out gene model provides molecular clues to breast cancer
7. PreMD Provides Update on 510(k) Application for PREVU(x) POC
8. SIV infection of natural hosts provides new insights into HIV disease complexity
9. Microarray provides 3 genomic guides to breast cancer treatment decisions
10. Access Innovations Provides Support Services for Agis Network
11. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 It is said that necessity ... to be true as a product sponsor for Lash ... Vegas this past June. , Lash Affair believes ... success of the eyelash industry through collaboration so Jenelle Paris, ... have supported NEESA ’s event. Lash Affair’s mission dovetails ...
(Date:7/30/2014)... July 30, 2014 Recently, Agebc.com, one ... industry, has released its new line of affordable ... girl dresses come in several popular styles: sequined ball-gown, ... designs in the company’s fresh assortment are: short chiffon ... by embroideries and of course the classic beautiful colored ...
(Date:7/30/2014)... study of high school students by University of Adelaide ... between insomnia-related mental health conditions among teens. , ... more than 300 Australian high school students aged 12-18 ... and the time of day they were most active ... in the journal Sleep Medicine , ...
(Date:7/30/2014)... could be created to diagnose diseases such as Alzheimer,s ... earlier intervention, according to new findings from the University ... components of memory using a combination of tests and ... create a diagnostic tool for distinguishing between different types ... amnesia caused by head trauma. , Dr Louis ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 4DSP’s new ... factor embedded system designed to provide a complete and ... communication. The system is housed in an enclosure measuring ... Kg. It features a low-power x86 CPU tightly coupled ... Mezzanine Card (FMC – VITA 57.1). The ...
Breaking Medicine News(10 mins):Health News:Lash Affair Launches a New Product as Sponsor of the First U.S. Lash Extension Competition 2Health News:Affordable Flower Girl Dresses Recently Unveiled at Agebc.com 2Health News:Teen insomnia is linked with depression and anxiety 2Health News:Hope for more accurate diagnosis of memory problems 2Health News:4DSP Introduces a Compact Platform for UAVs with Embedded Processing and Flexible IO 2Health News:4DSP Introduces a Compact Platform for UAVs with Embedded Processing and Flexible IO 3Health News:4DSP Introduces a Compact Platform for UAVs with Embedded Processing and Flexible IO 4
... Clinic have been able to find out subtle changes in ... of heart function by using the ultrasounds. They report that ... onset o heart damages like the heart attacks.// ,The ... optimal adjustment of cardiac pacemakers or perhaps better design of ...
... , it can be marketed as functional food ingredients, or ... they have been able to identify the molecular structure ... library of different flavonols. They also say that they are ... also compounds tailored to specific needs. , ,Several studies ...
... from tension-headaches, acupuncture may be the right treatment for ... that acupuncture can reduce the incidence of these headaches ... standard of clinical trials - researchers in Germany divided ... into three groups. ,Over an eight week ...
... and Lviv Regional Oncology center//, Ukraine has developed a ... of breast and ovarian cancer. ,However, they did ... to find a single reliable early protein, or 'marker', ... very successful," says LICR's Serhiy Souchelnytskyi, senior author of ...
... neurodegenerative and ultimately fatal disease// that slowly destroys the ... the ability to take care of themselves and require ... ,Based on findings of a recent study researchers say ... help slow the progression of Alzheimer's disease by reducing ...
... more than 21,100 consumers in 38 markets it was seen that ... fat content, while two in five people regularly check for calorie ... they understood food labeling, when they would check nutritional information and ... shopping. ,It was seen that in spite of all ...
Cached Medicine News:Health News:Ultrasounds To Detect Changes In Heart Motions 2Health News:Acupuncture May Be An Effective Treatment Against Tension-Headaches 2Health News:Molecular markers for early diagnosis of breast and ovarian cancer 2
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... 30, 2014  Packaging Coordinators, Inc. (PCI) is pleased ... acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is ... the United Kingdom and operates ... and Tokyo , Japan. Penn Pharma ... and Commercial dosage form manufacturing, as well as Clinical ...
(Date:7/30/2014)... LAKE FOREST, Ill., July 30, 2014  Hospira, ... leading provider of injectable drugs and infusion technologies, ... June 30, 2014. Net sales for the quarter ... share were $0.72. (Adjusted* measures exclude specified items ... the attached schedules.) On a U.S. Generally Accepted ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25
... Thirteen Abstracts Will Be Featured at Annual Kidney Care ... leading provider of kidney care services for those diagnosed ... with DaVita Clinical Research(R), today announced that company representatives ... 2009 Spring Clinical Meetings scheduled for March 25-29, 2009 ...
... Pharmaceuticals,Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a ... it has been selected to present the ... to Assess the Safety,Pharmacokinetics (PK) and Pharmacodynamics ... Type 2 Diabetes (T2DM)" at the upcoming ...
Cached Medicine Technology:DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 2DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 3DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 4DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 5Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA) 2
Use the Mo Bio Vortex Adapter in conjunction with the Vortex Genie 2 for rapid bead beating procedures. Using the Mo Bio Vortex Adapter is an inexpensive alternative to other bead beating and Fast Pr...
... V-500 with Vacuum Controller V-800 and water-cooled secondary ... Model V-500 is a powerful ... vacuum applications. Applications Ideally suited ... Laboratory vacuum source for instruments including ...
... with Vacuum Controller V-800 Efficiently controls vacuum ... on and off as needed to maintain preset vacuum ... PTFE membrane vacuum pump designed to handle most vacuum ... with up to two rotary evaporators Laboratory ...
... BchiVac V-500 and water-cooled secondary condenser to ... a powerful PTFE membrane vacuum pump designed ... Ideally suited for use with ... Laboratory vacuum source for instruments including vacuum ...
Medicine Products: